glp 1 drug names for weight loss list The Boom in New Drugs: What Prehospital Caregivers Need New GLP-1 weight loss drugs

Furthermore, the clinical evidence, primarily derived from large-scale retrospective analyses, shows a promising signal for glaucoma prevention

Real-world results vary based on dose, adherence, diet, activity level, and individual biology

GLP-1 receptor agonists are recommended as either first-line or second-line therapy regardless of baseline hemoglobin A1c in patients who have established atherosclerotic cardiovascular disease, high risk of atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure

These concerns are mainly based on rodent studies

September 2025: Pfizer announced its agreement to acquire Metsera in a deal valued at up to USD 7.3 billion, strengthening its pipeline of next-generation GLP-1, amylin, and obesity therapies